Coronavirus Notebook: Nobel Laureates Press Germany To Back Vaccine IP Waiver
The EU vaunts its vaccine donations and starts building resilience against future health threats, and the UK MHRA says Moderna can be used as a booster dose. Aviptadil has received scientific advice from the MHRA for its potential use as a treatment for COVID-19 patients.
You may also be interested in...
Coronavirus Notebook: EU & Australia Assessing Comirnaty In 5-11 Year Olds, Aviptadil Shows Promise In Critical COVID-19 Patients
The European Medicines Agency has OKd new manufacturing sites and a ready-to-use formulation for Comirnaty, while Australia has provisionally approved Ronapreve for treatment and post-exposure prophylaxis. The UK has secured supplies of two investigational antiviral products from Pfizer and MSD.
The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.
While the UK and other countries are implementing or considering additional vaccination campaigns, questions have been raised about the impact on lower-income countries, and COVAX has called on donors and manufactures to honor their vaccine supply commitments.